EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes

Marlene Santos, Luis Lima, Serafim Carvalho iD, Jorge Mota-Pereira, Paulo Pimentel, Dulce Maia, Diana Correia, M Fátima Barroso iD, Sofia Gomes, Agostinho Cruz iD, Rui Medeiros iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24076758 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Marlene Santos und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigação em Saúde e Ambiente (CISA), Escola Superior de Saúde, Instituto Politécnico do Porto, 4200-072 Porto, Portugal. Hauptthemen laut MEDLINE: Antidepressive Agents, Major Depressive Disorder. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca Fondation, AstraZeneca Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to investigate the influence of genetic variants in neuroplasticity-related genes on antidepressant treatment phenotypes. The BDNF-TrkB signaling pathway, as well as the downstream kinases Akt and ERK and the mTOR pathway, have been implicated in depression and neuroplasticity. However, clinicians still struggle with the unpredictability of antidepressant responses in depressed patients. We genotyped 26 polymorphisms in BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 in 80 patients with major depressive disorder treated according to the Texas Medical Algorithm for 27 months at Hospital Magalhães Lemos, Porto, Portugal. Our results showed that BDNF rs6265, PTEN rs12569998, and SYN1 rs1142636 SNP were associated with treatment-resistant depression (TRD). Additionally, MAPK1 rs6928 and GSK3B rs6438552 gene polymorphisms were associated with relapse. Moreover, we found a link between the rs6928 MAPK1 polymorphism and time to relapse. These findings suggest that the BDNF, PTEN, and SYN1 genes may play a role in the development of TRD, while MAPK1 and GSK3B may be associated with relapse. GO analysis revealed enrichment in synaptic and trans-synaptic transmission pathways and glutamate receptor activity with TRD-associated genes. Genetic variants in these genes could potentially be incorporated into predictive models of antidepressant response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antidepressive AgentsMajor Depressive DisorderHumansBrain-Derived Neurotrophic FactorNerve Tissue ProteinsPhenotypePolymorphism, Single NucleotideProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseReceptors, Nerve Growth FactorRecurrenceTOR Serine-Threonine KinasesCyclic AMP Response Element-Binding ProteinGlycogen Synthase Kinase 3 betaMitogen-Activated Protein Kinase 1

Stichwörter der Autor:innen

ADBDNFGSK3BMAPKPTENSYN1genetic polymorphismsneuroplasticitytreatment-resistant depression

Substanzen

Antidepressive AgentsBrain-Derived Neurotrophic FactorNerve Tissue ProteinsProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseReceptors, Nerve Growth FactorTOR Serine-Threonine KinasesCREB1 protein, humanCyclic AMP Response Element-Binding ProteinGSK3B protein, human

Autor:innen und Institutionen

  • Centro de Investigação em Saúde e Ambiente (CISA), Escola Superior de Saúde, Instituto Politécnico do Porto, 4200-072 Porto, Portugal.
  • Molecular Oncology & Viral Pathology, IPO-Porto Research Center (CI-IPOP), Portuguese Institute of Oncology, 4200-072 Porto, Portugal.
  • Experimental Pathology and Therapeutics Group, IPO-Porto Research Center (CI-IPOP), Portuguese Institute of Oncology, 4200-072 Porto, Portugal.
  • Hospital de Magalhães Lemos, 4149-003 Porto, Portugal.
  • Instituto Universitário de Ciências da Saúde, 4585-116 Gandra, Portugal.
  • Clínica Médico-Psiquiátrica da Ordem, 4000-270 Porto, Portugal.

ORCID-Profile: Serafim Carvalho, M Fátima Barroso, Agostinho Cruz, Rui Medeiros

Förderung

  • AstraZeneca Fondation
  • AstraZeneca Foundation

Zitieren

APA

Santos, M., Lima, L., Carvalho, S., Mota-Pereira, J., Pimentel, P., Maia, D., Correia, D., Barroso, M. F., Gomes, S., Cruz, A., & Medeiros, R. (2023). The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076758

Vancouver

Santos M, Lima L, Carvalho S, Mota-Pereira J, Pimentel P, Maia D, et al. The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24076758

BibTeX
@article{Santos2023,
  author = {Santos, Marlene and Lima, Luis and Carvalho, Serafim and Mota-Pereira, Jorge and Pimentel, Paulo and Maia, Dulce and Correia, Diana and Barroso, M Fátima and Gomes, Sofia and Cruz, Agostinho and Medeiros, Rui},
  title = {The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24076758}
}
Kostenlos starten →